Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05633810 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes

Study acronym: COLCOT-T2D
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 15 words
    • Site details revised at 15 of 39 sites
  2. Study sites: 1 to 39v8
  3. Re-verified, no change to tracked fieldsv7
  4. Site contact updated
    • Eligibility criteria expanded, about 1 word
    v6
  5. Primary and study completion dates: Dec 2026 to Dec 2027
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: details revised at 9 of 9 entries
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Re-verified, no change to tracked fieldsv4
  2. Start date changed from estimate of Dec 2022 to Dec 21, 2022v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Nov 2022 to Dec 2022
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Montreal Heart Institute
25 trials monitored
See 4 trials at risk
Heart Disease
8,786 trials monitored
See 412 trials at risk
Diabetes
5,087 trials monitored
See 222 trials at risk
Type 2 Diabetes
2,231 trials monitored
See 111 trials at risk
To evaluate the efficacy and safety of colchicine and non-enteric coated aspirin, combined or alone, to improve cardiovascular outcomes in high-risk patients with type 2 diabetes.
Trial Details
NCT Number NCT05633810
Lead Sponsor Montreal Heart Institute
Conditions
(from sponsor)		 Diabete Type 2, Cardiovascular Diseases
Related terms Cardiovascular Diseases, Diabetes Mellitus, Type 2, Heart Diseases
Enrollment 10,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov